This prospective cohort study of 196,129 women quantifies atypical femur fracture risk versus hip fractures prevented across 1–10 years of bisphosphonate use. Findings are stratified by race and treatment duration to enable individualized patient counseling. It directly addresses whether atypical femur fracture fears justify reduced bisphosphonate prescribing.
When atypical femur fracture reports emerged in the mid-2000s, bisphosphonate prescribing dropped dramatically — and hip fracture rates began rising again, suggesting that fear of a rare complication was causing real harm from undertreated osteoporosis.
For most postmenopausal White women with osteoporosis, this paper confirms that bisphosphonates should be continued: at 3 years, hip fractures prevented outnumber atypical femur fractures by roughly 75:1, and at 5 years by about 35:1.
For Asian women, start the drug holiday conversation earlier. The benefit margin narrows to near-parity by 10 years. Revisit the risk-benefit balance proactively after 5 years of use in this population. When you stop bisphosphonates for a drug holiday, reassure patients that risk drops by half within 3–15 months and by roughly 75% beyond 15 months. The holiday has a rapid, measurable payoff.
Flag patients on chronic glucocorticoids (1+ year) as a distinct high-risk group for atypical femur fracture monitoring, regardless of race. Low bone mineral density and prior fracture. The usual osteoporosis red flags. Do not apply here.
This prospective cohort study of 196,129 women quantifies atypical femur fracture risk versus hip fractures prevented across 1–10 years of bisphosphonate use. Findings are stratified by race and treatment duration to enable individualized patient counseling. It directly addresses whether atypical femur fracture fears justify reduced bisphosphonate prescribing.
When atypical femur fracture reports emerged in the mid-2000s, bisphosphonate prescribing dropped dramatically — and hip fracture rates began rising again, suggesting that fear of a rare complication was causing real harm from undertreated osteoporosis.
For most postmenopausal White women with osteoporosis, this paper confirms that bisphosphonates should be continued: at 3 years, hip fractures prevented outnumber atypical femur fractures by roughly 75:1, and at 5 years by about 35:1.
For Asian women, start the drug holiday conversation earlier. The benefit margin narrows to near-parity by 10 years. Revisit the risk-benefit balance proactively after 5 years of use in this population. When you stop bisphosphonates for a drug holiday, reassure patients that risk drops by half within 3–15 months and by roughly 75% beyond 15 months. The holiday has a rapid, measurable payoff.
Flag patients on chronic glucocorticoids (1+ year) as a distinct high-risk group for atypical femur fracture monitoring, regardless of race. Low bone mineral density and prior fracture. The usual osteoporosis red flags. Do not apply here.